Sarepta competitor files with FDA for Duchenne drug

Sarepta Therapeutics (NASDAQ:SRPT) -3% pre-market after Japanese drugmaker NS Pharma said it filed with the U.S. Food and Drug Administration to seek approval for its new drug to treat Duchenne muscular dystrophy.

If approved, the NS Pharma drug would be the first treatment for children born with Duchenne caused by a mutation in the DNA.

In August, the FDA raised concerns about SRPT’s New Drug Application seeking accelerated approval of golodirsen injection for treatment of DMD.

https://seekingalpha.com/news/3503331-sarepta-competitor-files-fda-duchenne-drug